nach oben

Erschienen in:

14.07.2020 | TAVI | Konsensuspapiere

Kontrastmittelinduzierte akute Nierenschädigung – Konsensuspapier der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. und der Deutschen Gesellschaft für Nephrologie e. V.

verfasst von: J. Latus, V. Schwenger, G. Schlieper, H. Reinecke, J. Hoyer, P. B. Persson, B. A. Remppis, Prof. Dr. med. F. Mahfoud

Erschienen in: Die Kardiologie | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Dieses Konsensuspapier ist eine Stellungnahme der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. und der Deutschen Gesellschaft für Nephrologie e. V. zum Thema kontrastmittelinduzierte akute Nierenschädigung. Potenziell nierenschädigendes jodhaltiges Kontrastmittel wird in der interventionellen Medizin und der Computertomographiediagnostik häufig eingesetzt. Eine akute Nierenschädigung tritt bei etwa 8–17 % der Patienten auf. Es werden Risikofaktoren und die zugrunde liegende Pathogenese diskutiert und Empfehlungen zur Prophylaxe und Therapie kontrastmittelinduzierter akuter Nierenschädigungen vorgestellt.

Abe M, Morimoto T, Akao M et al (2014) Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol 114:362–368. https://doi.org/10.1016/j.amjcard.2014.05.009CrossRefPubMed

Agmon Y, Peleg H, Greenfeld Z et al (1994) Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 94:1069–1075. https://doi.org/10.1172/JCI117421CrossRefPubMedPubMedCentral

Andrassy KM (2013) Comments on “KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease”. Kidney Int 84:622–623. https://doi.org/10.1038/ki.2013.243CrossRefPubMed

Aslan G, Afsar B, Sag AA et al (2020) The effect of urine ph and urinary uric acid levels on the development of contrast nephropathy. Kidney Blood Press Res 45:131–141. https://doi.org/10.1159/000504547CrossRefPubMed

Bainey KR, Rahim S, Etherington K et al (2015) Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: results from the angiotensin converting enzyme inhibitor/angiotensin receptor bloc. Am Heart J 170:110–116. https://doi.org/10.1016/j.ahj.2015.04.019CrossRefPubMed

Barbanti M, Gulino S, Capranzano P et al (2015) Acute kidney injury with the renalguard system in patients undergoing transcatheter aortic valve replacement: the PROTECT-TAVI trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation). JACC Cardiovasc Interv 8:1595–1604. https://doi.org/10.1016/j.jcin.2015.07.012CrossRefPubMed

Berwanger O (2011) Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation 124:1250–1259. https://doi.org/10.1161/CIRCULATIONAHA.111.038943CrossRef

Brar SS, Aharonian V, Mansukhani P et al (2014) Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: The POSEIDON randomised controlled trial. Lancet 383:1814–1823. https://doi.org/10.1016/S0140-6736(14)60689-9CrossRef

Brinjikji W, Demchuk AM, Murad MH et al (2017) Neurons over nephrons. Stroke 48:1862–1868. https://doi.org/10.1161/STROKEAHA.117.016771CrossRefPubMed

10.

Bruce RJ, Djamali A, Shinki K et al (2009) Background fluctuation of kidney function versus contrast-induced nephrotoxicity. AJR Am J Roentgenol 192:711–718. https://doi.org/10.2214/AJR.08.1413CrossRefPubMed

11.

Cruz DN, Goh CY, Marenzi G et al (2012) Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med. https://doi.org/10.1016/j.amjmed.2011.06.029CrossRefPubMed

12.

Dangas G, Iakovou I, Nikolsky E et al (2005) Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 95:13–19. https://doi.org/10.1016/j.amjcard.2004.08.056CrossRefPubMed

13.

Davenport MS, Khalatbari S, Dillman JR et al (2013) Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology 267:94–105. https://doi.org/10.1148/radiol.12121394CrossRefPubMedPubMedCentral

14.

Davenport MS, Perazella MA, Yee J et al (2020) Use of intravenous iodinated contrast media in patients with kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology 294:660–668. https://doi.org/10.1148/radiol.2019192094CrossRefPubMed

15.

Detrenis S, Meschi M, Musini S, Savazzi G (2005) Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 20:1542–1550. https://doi.org/10.1093/ndt/gfh868CrossRefPubMed

16.

Fähling M, Seeliger E, Patzak A, Persson PB (2017) Understanding and preventing contrast-induced acute kidney injury. Nat Rev Nephrol 13:169–180. https://doi.org/10.1038/nrneph.2016.196CrossRefPubMed

17.

Feldkamp T, Luedemann M, Spehlmann ME et al (2018) Radial access protects from contrast media induced nephropathy after cardiac catheterization procedures. Clin Res Cardiol 107:148–157. https://doi.org/10.1007/s00392-017-1166-2CrossRefPubMed

18.

Fishbane S (2008) N‑acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 3:281–287. https://doi.org/10.2215/CJN.02590607CrossRefPubMed

19.

From AM, Bartholmai BJ, Williams AW et al (2008) Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc 83:1095–1100. https://doi.org/10.4065/83.10.1095CrossRefPubMed

20.

Giacoppo D, Madhavan MV, Baber U et al (2015) Impact of contrast-induced acute kidney injury after percutaneous coronary intervention on short- and long-term outcomes: Pooled analysis from the HORIZONS-AMI and ACUITY trials. Circ Cardiovasc Interv 8:2259–2264. https://doi.org/10.1161/CIRCINTERVENTIONS.114.002475CrossRef

21.

Gilstrap LG, Fonarow GC, Desai AS et al (2017) Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J Am Heart Assoc 6:e4675. https://doi.org/10.1161/JAHA.116.004675CrossRefPubMedPubMedCentral

22.

Gutierrez NM, Newhouse JH (2017) Maximum arterial contrast concentrations with computed tomography and left ventriculography: implications for contrast nephrotoxicity risk. J Comput Assist Tomogr 41:976–982. https://doi.org/10.1097/RCT.0000000000000624CrossRef

23.

Halliday BP, Wassall R, Lota AS et al (2019) Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 393:61–73. https://doi.org/10.1016/S0140-6736(18)32484-XCrossRefPubMedPubMedCentral

24.

Hayek SS, Leaf DE, Tahhan AS et al (2020) Soluble urokinase receptor and acute kidney injury. N Engl J Med 382:416–426. https://doi.org/10.1056/NEJMoa1911481CrossRefPubMedPubMedCentral

25.

Heyman SN, Rosenberger C, Rosen S (2005) Regional alterations in renal haemodynamics and oxygenation: A role in contrast medium-induced nephropathy. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfh1069CrossRefPubMed

26.

Hinson JS, Ehmann MR, Fine DM et al (2017) Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med 69:577–586.e4. https://doi.org/10.1016/j.annemergmed.2016.11.021CrossRef

27.

James MT, Ghali WA, Tonelli M et al (2010) Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int 78:803–809. https://doi.org/10.1038/ki.2010.258CrossRefPubMed

28.

Kellum JA, Lameire N, Aspelin P et al (2012) Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138. https://doi.org/10.1038/kisup.2012.1CrossRef

29.

Klima T, Christ A, Marana I et al (2012) Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. Eur Heart J 33:2071–2079. https://doi.org/10.1093/eurheartj/ehr501CrossRefPubMed

30.

Kong DG, Hou YF, Le Ma L et al (2012) Comparison of oral and intravenous hydration strategies for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography or angioplasty: a randomized clinical trial. Acta Cardiol 67:565–569. https://doi.org/10.2143/AC.67.5.2174131CrossRefPubMed

31.

Kshirsagar AV, Poole C, Mottl A et al (2004) N‑Acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 15:761–769. https://doi.org/10.1097/01.ASN.0000116241.47678.49CrossRefPubMed

32.

Leoncini M, Toso A, Maioli M et al (2014) Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol 63:71–79. https://doi.org/10.1016/j.jacc.2013.04.105CrossRefPubMed

33.

Li H, Wang C, Liu C et al (2016) Efficacy of short-term statin treatment for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention: a meta-analysis of 21 randomized controlled trials. Am J Cardiovasc Drugs 16:201–219. https://doi.org/10.1007/s40256-016-0164-5CrossRefPubMed

34.

Liss P, Persson PB, Hansell P, Lagerqvist B (2006) Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 70:1811–1817. https://doi.org/10.1038/sj.ki.5001887CrossRefPubMed

35.

Marashizadeh A, Sanati HR, Sadeghipour P et al (2019) Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial. Int Urol Nephrol 51:1815–1822. https://doi.org/10.1007/s11255-019-02235-wCrossRefPubMed

36.

Marenzi G, Ferrari C, Marana I et al (2012) Prevention of contrast nephropathy by furosemide with matched hydration: The MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC Cardiovasc Interv 5:90–97. https://doi.org/10.1016/j.jcin.2011.08.017CrossRefPubMed

37.

McCullough PA, Wolyn R, Rocher LL et al (1997) Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 103:368–375. https://doi.org/10.1016/S0002-9343(97)00150-2CrossRefPubMed

38.

McCullough PA, Zhang J, Ronco C (2017) Volume expansion and contrast-induced acute kidney injury. Lancet 389:1277–1278. https://doi.org/10.1016/S0140-6736(17)30540-8CrossRef

39.

McDonald JS, McDonald RJ, Lieske JC et al (2015) Risk of acute kidney injury, dialysis, and mortality in patients with chronic kidney disease after intravenous contrast material exposure. Mayo Clin Proc 90:1046–1053. https://doi.org/10.1016/j.mayocp.2015.05.016CrossRefPubMedPubMedCentral

40.

McDonald JS, McDonald RJ, Williamson EE et al (2017) Post-contrast acute kidney injury in intensive care unit patients: a propensity score-adjusted study. Intensive Care Med 43:774–784. https://doi.org/10.1007/s00134-017-4699-yCrossRefPubMed

41.

McDonald RJ, McDonald JS, Bida JP et al (2013) Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 267:106–118. https://doi.org/10.1148/radiol.12121823CrossRefPubMedPubMedCentral

42.

Mehran R, Aymong ED, Nikolsky E et al (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44:1393–1399. https://doi.org/10.1016/j.jacc.2004.06.068CrossRef

43.

Michael A, Faga T, Pisani A et al (2014) Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. Biomed Res Int 2014:249810. https://doi.org/10.1155/2014/249810CrossRefPubMedPubMedCentral

44.

Morcos SK, Thomsen HS, Webb JAW (1999) Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 9:1602–1613. https://doi.org/10.1007/s003300050894CrossRefPubMed

45.

Newhouse JH, Kho D, Rao QA, Starren J (2008) Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 191:376–382. https://doi.org/10.2214/AJR.07.3280CrossRefPubMed

46.

Nijssen EC, Nelemans PJ, Rennenberg RJ et al (2018) Evaluation of safety guidelines on the use of Iodinated contrast material: conundrum continued. Invest Radiol 53:616–622. https://doi.org/10.1097/RLI.0000000000000479CrossRefPubMed

47.

Nijssen EC, Rennenberg RJ, Nelemans PJ et al (2017) Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 389:1312–1322. https://doi.org/10.1016/S0140-6736(17)30057-0CrossRef

48.

O’Leary JM, Assad TR, Xu M et al (2017) Pulmonary hypertension in patients with chronic kidney disease: Invasive hemodynamic etiology and outcomes. Pulm Circ 7:674–683. https://doi.org/10.1177/2045893217716108CrossRefPubMedPubMedCentral

49.

Panagiotou A, Trendelenburg M, Heijnen IAFM et al (2020) A randomized trial of recombinant human C1-esterase-inhibitor in the prevention of contrast-induced kidney injury. JACC Cardiovasc Interv 13:833–842. https://doi.org/10.1016/j.jcin.2019.11.021CrossRefPubMed

50.

Parikh CR, Liu C, Mor MK et al (2020) Kidney biomarkers of injury and repair as predictors of contrast-associated AKI: a substudy of the PRESERVE trial. Am J Kidney Dis 75:187–194. https://doi.org/10.1053/j.ajkd.2019.06.011CrossRefPubMed

51.

Persson PB, Tepel M (2006) Contrast medium-induced nephropathy: the pathophysiology. Kidney Int 69:S8–S10. https://doi.org/10.1038/sj.ki.5000367CrossRef

52.

Rihal CS, Textor SC, Grill DE et al (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259–2264. https://doi.org/10.1161/01.CIR.0000016043.87291.33CrossRefPubMed

53.

Rudnick MR, Goldfarb S, Wexler L et al (1995) Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 47:254–261CrossRef

54.

Saito Y, Watanabe M, Aonuma K et al (2015) Proteinuria and reduced estimated glomerular filtration rate are independent risk factors for contrast-induced nephropathy after cardiac catheterization. Circ J 79:1624–1630. https://doi.org/10.1253/circj.CJ-14-1345CrossRefPubMed

55.

Schönenberger E, Martus P, Bosserdt M et al (2019) Kidney injury after intravenous versus intra-arterial contrast agent in patients suspected of having coronary artery disease: a randomized trial. Radiology 292:664–672. https://doi.org/10.1148/radiol.2019182220CrossRefPubMed

56.

Seeliger E, Lenhard DC, Persson PB (2014) Contrast media viscosity versus osmolality in kidney injury: lessons from animal studies. Biomed Res Int 2014:358136. https://doi.org/10.1155/2014/358136CrossRefPubMedPubMedCentral

57.

STARSurg Collaborative, McLean KA, Ahmed WUR, Akhbari M et al (2020) Perioperative intravenous contrast administration and the incidence of acute kidney injury after major gastrointestinal surgery: prospective, multicentre cohort study. Br J Surg. https://doi.org/10.1002/bjs.11453CrossRef

58.

Stevens MA, McCullough PA, Tobin KJ et al (1999) A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of the P.R.I.N.C.E. study. J Am Coll Cardiol 33:403–411. https://doi.org/10.1016/S0735-1097(98)00574-9CrossRef

59.

Susantitaphong P, Cruz DN, Cerda J et al (2013) World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol 8:1482–1493. https://doi.org/10.2215/CJN.00710113CrossRefPubMedPubMedCentral

60.

Trivedi HS, Moore H, Nasr S et al (2003) A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 93:C29–C34. https://doi.org/10.1159/000066641CrossRefPubMed

61.

Tsai TT, Patel UD, Chang TI et al (2014) Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: Insights from the National Cardiovascular Data Registry Cath-PCI registry. J Am Heart Assoc 3:e1380. https://doi.org/10.1161/JAHA.114.001380CrossRefPubMedPubMedCentral

62.

Valle JA, McCoy LA, Maddox TM et al (2017) Longitudinal risk of adverse events in patients with acute kidney injury after percutaneous coronary intervention. Circ Cardiovasc Interv 10:e4439. https://doi.org/10.1161/CIRCINTERVENTIONS.116.004439CrossRefPubMed

63.

Visconti G, Focaccio A, Donahue M et al (2016) RenalGuard System for the prevention of acute kidney injury in patients undergoing transcatheter aortic valve implantation. EuroIntervention 11:e1658–e1661. https://doi.org/10.4244/EIJV11I14A317CrossRefPubMed

64.

Vogt B, Ferrari P, Schönholzer C et al (2001) Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111:692–698. https://doi.org/10.1016/S0002-9343(01)00983-4CrossRef

65.

Weisbord SD, Chen H, Stone RA et al (2006) Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 17:2871–2877. https://doi.org/10.1681/ASN.2006030301CrossRefPubMed

66.

Weisbord SD, Gallagher M, Jneid H et al (2018) Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 378:603–614. https://doi.org/10.1056/NEJMoa1710933CrossRef

67.

Wilhelm-Leen E, Montez-Rath ME, Chertow G (2017) Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol 28:653–659. https://doi.org/10.1681/ASN.2016010021CrossRefPubMed

Titel: Kontrastmittelinduzierte akute Nierenschädigung – Konsensuspapier der Arbeitsgemeinschaft „Herz – Niere“ der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. und der Deutschen Gesellschaft für Nephrologie e. V.
verfasst von: J. Latus
V. Schwenger
G. Schlieper
H. Reinecke
J. Hoyer
P. B. Persson
B. A. Remppis
Prof. Dr. med. F. Mahfoud
Publikationsdatum: 14.07.2020
Verlag: Springer Medizin
Schlagwörter: TAVI
Akutes Nierenversagen
Akutes Nierenversagen
Erschienen in: Die Kardiologie / Ausgabe 6/2020
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-020-00411-2

Passend zum Thema

Leitlinien-Update und neue Pocket-Leitlinie vorgestellt von Prof. Möllmann

Vorhofflimmern

Die neue Leitlinie zur Behandlung von Herzklappenerkrankungen der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS) ist ab jetzt als deutschsprachige Pocket-Leitlinien abrufbar. Die wichtigsten Neuerungen des Updates finden Sie hier von Prof. Dr. Helge Möllmann aus Dortmund für Sie zusammengefasst.

Expertenrat: Wer profitiert vom Vorhofohr-Verschluss

Vorhofflimmern

Der interventionelle Verschluss des linken Vorhofohrs ist eine in den Leitlinien empfohlene Alternative zur oralen Antikoagulation bei Menschen mit Vorhofflimmern. Bei welchen Patientinnen und Patienten Sie konkret an diese Alternative denken sollten – dazu gibt Kardiologe PD Dr. Zisis Dimitriadis alltagstaugliche Tipps.

Abbott Structural Heart

Content Hub

Wir helfen Menschen mit Strukturellen Herzerkrankungen ihre Lebensqualität zu verbessern. Entdecken Sie unser einzigartiges Produktportfolio für ihre Patienten.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Subklinische Thrombosierung von Aortenklappenbioprothesen – Erkenntnisse der PARTNER-3-Studie

POPular-Studie: Renaissance von Clopidogrel für ältere Patienten mit Nicht-ST-Hebungsinfarkt?

Dramatischer Verlauf mit überraschender Wende: Woher kam der "Draht" im Brustkorb?

Erratum zu: Kommentar zu den Leitlinien (2019) der European Society of Cardiology (ESC) zu „Diabetes, Prädiabetes und kardiovaskuläre Erkrankungen“

Kommentar zu den Leitlinien (2019) der ESC zum chronischen Koronarsyndrom

Barorezeptoraktivierungstherapie bei Herzinsuffizienz mit reduzierter systolischer Funktion

Passend zum Thema

Leitlinien-Update und neue Pocket-Leitlinie vorgestellt von Prof. Möllmann

Expertenrat: Wer profitiert vom Vorhofohr-Verschluss

Abbott Structural Heart